Cancer Epidemiology
Volume 34, Issue 2 , Pages 200-206 , April 2010

Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by Polymerase Chain Reaction arrays in human prostate cancer cell lines

  • Nadège Rabiau

      Affiliations

    • Centre Jean Perrin, Department of Oncogenetics, EA 4233, Centre Biomédical de Recherche et de Valorisation, 28 place Henri Dunant, B.P. 38, 63011 Clermont-Ferrand, France
    • CNRH, 58 rue Montalembert, 63009 Clermont-Ferrand, France
    • Soluscience, Biopôle Clermont-Limagne, 63360 Saint-Beauzire, France
    • ,
  • Myriam Kossaï

      Affiliations

    • Centre Jean Perrin, Department of Oncogenetics, EA 4233, Centre Biomédical de Recherche et de Valorisation, 28 place Henri Dunant, B.P. 38, 63011 Clermont-Ferrand, France
    • CNRH, 58 rue Montalembert, 63009 Clermont-Ferrand, France
    • ,
  • Martin Braud

      Affiliations

    • Centre Jean Perrin, Department of Oncogenetics, EA 4233, Centre Biomédical de Recherche et de Valorisation, 28 place Henri Dunant, B.P. 38, 63011 Clermont-Ferrand, France
    • CNRH, 58 rue Montalembert, 63009 Clermont-Ferrand, France
    • ,
  • Nasséra Chalabi

      Affiliations

    • Centre Jean Perrin, Department of Oncogenetics, EA 4233, Centre Biomédical de Recherche et de Valorisation, 28 place Henri Dunant, B.P. 38, 63011 Clermont-Ferrand, France
    • CNRH, 58 rue Montalembert, 63009 Clermont-Ferrand, France
    • ,
  • Samir Satih

      Affiliations

    • Centre Jean Perrin, Department of Oncogenetics, EA 4233, Centre Biomédical de Recherche et de Valorisation, 28 place Henri Dunant, B.P. 38, 63011 Clermont-Ferrand, France
    • CNRH, 58 rue Montalembert, 63009 Clermont-Ferrand, France
    • ,
  • Yves-Jean Bignon

      Affiliations

    • Centre Jean Perrin, Department of Oncogenetics, EA 4233, Centre Biomédical de Recherche et de Valorisation, 28 place Henri Dunant, B.P. 38, 63011 Clermont-Ferrand, France
    • CNRH, 58 rue Montalembert, 63009 Clermont-Ferrand, France
    • Université Clermont I, Faculté de Médecine, 28 place Henri Dunant, 63001 Clermont-Ferrand Cedex 01, France
    • Corresponding Author InformationCorresponding author at: Centre Jean Perrin, Department of Oncogenetics, EA 4233, Centre Biomédical de Recherche et de Valorisation, 28 place Henri Dunant, B.P. 38, 63011 Clermont-Ferrand, France. Tel.: +33 04 73 27 81 48; fax: +33 04 73 27 80 42.
    • ,
  • Dominique J. Bernard-Gallon

      Affiliations

    • Centre Jean Perrin, Department of Oncogenetics, EA 4233, Centre Biomédical de Recherche et de Valorisation, 28 place Henri Dunant, B.P. 38, 63011 Clermont-Ferrand, France
    • CNRH, 58 rue Montalembert, 63009 Clermont-Ferrand, France

,Accepted 30 December 2009.

References 

  1. Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, et al. Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer. 2003;10:225–259
  2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108
  3. Colonna M, Danzon A, Delafosse P, Mitton N, Bara S, Bouvier AM, et al. Cancer prevalence in France: time trend, situation in 2002 and extrapolation to 2012. Eur J Cancer. 2008;44:115–122
  4. Hill C, Doyon F. The frequency of cancer in France in year 2000, and trends since 1950. Bull Cancer. 2005;92:7–11
  5. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85:60–67
  6. Cook LS, Goldoft M, Schwartz SM, Weiss NS. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 1999;161:152–155
  7. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer. 1991;63:963–966
  8. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer. 2005;41:834–845
  9. Magee PJ, Rowland IR. Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br J Nutr. 2004;91:513–531
  10. Messina MJ. Emerging evidence on the role of soy in reducing prostate cancer risk. Nutr Rev. 2003;61:117–131
  11. Messina M, Kucuk O, Lampe JW. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J AOAC Int. 2006;89:1121–1134
  12. Nakamura Y, Tsuji S, Tonogai Y. Determination of the levels of isoflavonoids in soybeans and soy-derived foods and estimation of isoflavonoids in the Japanese daily intake. J AOAC Int. 2000;83:635–650
  13. Steiner C, Arnould S, Scalbert A, Manach C. Isoflavones and the prevention of breast and prostate cancer: new perspectives opened by nutrigenomics. Br J Nutr. 2008;99(E Suppl. 1):ES78–ES108
  14. Pollard M, Suckow MA. Dietary prevention of hormone refractory prostate cancer in Lobund-Wistar rats: a review of studies in a relevant animal model. Comp Med. 2006;56:461–467
  15. Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein suppresses chemically induced prostate cancer in Lobund-Wistar rats. Cancer Lett. 2002;186:11–18
  16. Hedlund TE, Johannes WU, Miller GJ. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate. 2003;54:68–78
  17. Fang MZ, Chen D, Sun Y, Jin Z, Christman JK, Yang CS. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin Cancer Res. 2005;11:7033–7041
  18. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 2005;65:6934–6942
  19. Barnes S, Peterson TG. Biochemical targets of the isoflavone genistein in tumor cell lines. Proc Soc Exp Biol Med. 1995;208:103–108
  20. Satih S, Rabiau N, Bignon YJ, Bernard-Gallon DJ. Soy phytoestrogens and breast cancer chemoprevention: molecular mechanisms. Curr Nutr Food Sci. 2008;4:259–264
  21. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA. 1993;90:2690–2694
  22. Fotsis T, Pepper M, Adlercreutz H, Hase T, Montesano R, Schweigerer L. Genistein, a dietary ingested isoflavonoid, inhibits cell proliferation and in vitro angiogenesis. J Nutr. 1995;125:790S–797S
  23. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol. 1975;66:188–193
  24. Favy DA, Lafarge S, Rio P, Vissac C, Bignon YJ, Bernard-Gallon D. Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines. Biochem Biophys Res Commun. 2000;274:73–78
  25. Oki T, Sowa Y, Hirose T, Takagaki N, Horinaka M, Nakanishi R, et al. Genistein induces Gadd45 gene and G2/M cell cycle arrest in the DU145 human prostate cancer cell line. FEBS Lett. 2004;577:55–59
  26. Shenouda NS, Zhou C, Browning JD, Ansell PJ, Sakla MS, Lubahn DB, et al. Phytoestrogens in common herbs regulate prostate cancer cell growth in vitro. Nutr Cancer. 2004;49:200–208
  27. Kobayashi T, Nakata T, Kuzumaki T. Effect of flavonoids on cell cycle progression in prostate cancer cells. Cancer Lett. 2002;176:17–23
  28. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817–825
  29. Gartel AL, Tyner AL. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002;1:639–649
  30. Handayani R, Rice L, Cui Y, Medrano TA, Samedi VG, Baker HV, et al. Soy isoflavones alter expression of genes associated with cancer progression, including interleukin-8, in androgen-independent PC-3 human prostate cancer cells. J Nutr. 2006;136:75–82
  31. Karan D, Kelly DL, Rizzino A, Lin MF, Batra SK. Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis. 2002;23:967–975
  32. Ko LJ, Shieh SY, Chen X, Jayaraman L, Tamai K, Taya Y, et al. p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Mol Cell Biol. 1997;17:7220–7229
  33. Padmanabhan V, Callas P, Philips G, Trainer TD, Beatty BG. DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J Clin Pathol. 2004;57:1057–1062
  34. Takisawa H, Mimura S, Kubota Y. Eukaryotic DNA replication: from pre-replication complex to initiation complex. Curr Opin Cell Biol. 2000;12:690–696
  35. Berner A, Geitvik G, Karlsen F, Fossa SD, Nesland JM, Borresen AL. TP53 mutations in prostatic cancer. Analysis of pre- and post-treatment archival formalin-fixed tumour tissue. J Pathol. 1995;176:299–308
  36. Zheng L, Wang F, Qian C, Neumann RM, Cheville JC, Tindall DJ, et al. Unique substitution of CHEK2 and TP53 mutations implicated in primary prostate tumors and cancer cell lines. Hum Mutat. 2006;27:1062–1063
  37. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol. 2000;60:1051–1059
  38. Aragon-Ching JB, Dahut WL. The role of angiogenesis inhibitors in prostate cancer. Cancer J. 2008;14:20–25
  39. Li Y, Sarkar FH. Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett. 2002;186:157–164
  40. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, et al. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 1987;262:5592–5595
  41. Wang J, Eltoum IE, Lamartiniere CA. Genistein chemoprevention of prostate cancer in TRAMP mice. J Carcinog. 2007;6:3
  42. Gadgeel SM, Ali S, Philip PA, Wozniak A, Sarkar FH. Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines. Cancer. 2009;115:2165–2176
  43. Zhang J, Hughes S. Role of the ephrin and Eph receptor tyrosine kinase families in angiogenesis and development of the cardiovascular system. J Pathol. 2006;208:453–461
  44. Buzza M, Dagher H, Wang YY, Wilson D, Babon JJ, Cotton RG, et al. Mutations in the COL4A4 gene in thin basement membrane disease. Kidney Int. 2003;63:447–453
  45. Lehrer S, Diamond EJ, Mamkine B, Stone NN, Stock RG. Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol Cancer Res Treat. 2004;3:411
  46. Trojan L, Schaaf A, Steidler A, Haak M, Thalmann G, Knoll T, et al. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res. 2005;25:183–191
  47. Engl T, Relja B, Blumenberg C, Muller I, Ringel EM, Beecken WD, et al. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci. 2006;78:1784–1793
  48. Lendeckel U, Arndt M, Frank K, Wex T, Ansorge S. Role of alanyl aminopeptidase in growth and function of human T cells (review). Int J Mol Med. 1999;4:17–27
  49. Ishii K, Usui S, Sugimura Y, Yamamoto H, Yoshikawa K, Hirano K. Inhibition of aminopeptidase N (AP-N) and urokinase-type plasminogen activator (uPA) by zinc suppresses the invasion activity in human urological cancer cells. Biol Pharm Bull. 2001;24:226–230

PII: S1877-7821(10)00003-2

doi: 10.1016/j.canep.2009.12.018

Cancer Epidemiology
Volume 34, Issue 2 , Pages 200-206 , April 2010

Article Tools

* Image Usage & Resolution